ADVERTISEMENT

NewsThailand

Thai Healthcare Now Includes Hormone Therapy for LGBTQ+

The Ministry of Public Health has approved a 145-million-baht benefit to provide gender-affirming hormone therapy for transgender and gender-diverse individuals under Thailand’s 30-baht universal healthcare scheme.

Public Health Minister Somsak Thepsuthin, who also chairs the National Health Security Office (NHSO) board, has endorsed the inclusion of six hormone-related medications in the national procurement list.

The move is part of the “Treatment Anywhere” initiative, a key component of the country’s low-cost healthcare programme.

The approved medications include leuprorelin injections, 17-beta estradiol tablets, estradiol transdermal patches, testosterone enanthate injections, cyproterone acetate tablets, and spironolactone tablets.

Jirapong Songwatcharaporn, deputy spokesman for the Public Health Ministry, said the decision addresses increasing concerns over the risks associated with unsupervised hormone use among transgender individuals.

He noted that improper self-medication using over-the-counter drugs without medical oversight has resulted in severe side effects and, in some cases, fatalities.

“Doctors will conduct a thorough review of each patient’s medical history and overall health, assess their mental readiness, and discuss the methods and procedures before starting hormone treatment,” Mr. Jirapong said.

According to the ministry, the new benefit is expected to reduce the risk of harm from improper hormone use and lower out-of-pocket expenses for transgender individuals by approximately 1,000 to 2,000 baht per month.

The policy is being rolled out in collaboration with the Health Systems Research Institute (HSRI), the Royal Thai College of Obstetricians and Gynaecologists, and the Thailand Professional Association of Transgender Health (ThaiPATH).